Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the lining of the colon, causing persistent symptoms such as abdominal pain, diarrhea, and rectal bleeding. With an estimated 3.2 million diagnosed cases across major markets in 2024 — and approximately 60% of those classified as moderate to severe — the demand for better, safer therapies has never been greater. Fortunately, the UC treatment pipeline is rich with promise, and patients today have more options than ever before.
What Is the Best Medicine for Ulcerative Colitis?
What is the best medicine for ulcerative colitis depends heavily on disease severity and a patient's treatment history. Broadly, UC therapies fall into several categories: conventional treatments like aminosalicylates and corticosteroids, biologics such as anti-TNF agents and integrin inhibitors, S1P-receptor modulators, and JAK inhibitors. Newer mechanisms — including LANCL2 protein stimulators and miR-124 enhancers — are now broadening this toolkit further.
What Is the Latest Treatment for Ulcerative Colitis?
What is the latest treatment for ulcerative colitis? One of the most significant recent milestones was the FDA approval of SKYRIZI (risankizumab) by AbbVie in June 2024, making it the first IL-23 inhibitor approved for both Crohn's disease and ulcerative colitis. Patients can self-administer it at home via an on-body injector after an initial induction period — a meaningful convenience upgrade for those managing a lifelong condition.
Researchers and clinicians continue to ask what is the latest treatment for ulcerative colitis as the pipeline evolves rapidly, with several Phase III readouts expected through 2026 reshaping the standard of care.
New Treatment for Ulcerative Colitis 2025
New treatment for ulcerative colitis 2025 headlines are being driven by a wave of pivotal clinical readouts. At Digestive Disease Week 2025, Janssen's TREMFYA (guselkumab) reported Phase III long-term extension data showing that 72% of treated patients maintained clinical remission at Week 92 — with 99% remaining corticosteroid-free. Meanwhile, Omilancor from Landos Biopharma/NImmune showed clinical remission in over 30% of patients at the Phase 3 dose, with observable biomarker improvements within just two weeks of starting therapy.
New Ulcerative Colitis Medications Entering the Pipeline
New ulcerative colitis medications are advancing across multiple stages of development. Here's a snapshot of the most closely watched candidates:
ABX464 (Obefazimod) by Abivax — a first-in-class oral molecule that selectively amplifies miR-124 expression in immune cells, currently in Phase III with NDA submission targeted for the first half of 2026.
Tulisokibart (MK-7240) by Merck — a humanized monoclonal antibody targeting TNF-like ligand 1A (TL1A), in Phase III with strong Phase II results.
MORF-057 by Eli Lilly — an oral integrin inhibitor designed to rival vedolizumab without injection, currently in Phase II after Eli Lilly's acquisition of Morphic Holding.
TAK-279 by Takeda — a highly selective oral TYK2 inhibitor in Phase II with strong affinity advantages over older JAK inhibitors.
Remestemcel-L by Mesoblast Ltd. — a mesenchymal stem cell therapy in Phase I/II, exploring a completely novel immunomodulatory approach.
Medications for Ulcerative Colitis: What's Already Approved
Medications for ulcerative colitis that are already FDA-approved include a robust roster: SIMPONI, ENTYVIO, XELJANZ/XELJANZ XR, STELARA, RINVOQ, ZEPOSIA, REMICADE, HUMIRA, OMVOH, SKYRIZI, and others. SIMPONI notably holds the distinction of being the first subcutaneous anti-TNF therapy administered just once every four weeks as maintenance — a standard-setter in the field.
New Drugs for Ulcerative Colitis: Precision Over Broad Suppression
New drugs for ulcerative colitis are increasingly built on precision biology. Rather than broadly suppressing the immune system — which raises infection and malignancy risks — next-generation therapies target specific inflammatory pathways such as IL-23, TL1A, α4β7 integrin, and TYK2. This means fewer systemic side effects and more durable remission, which directly translates into improved quality of life and reduced long-term healthcare costs.
New Treatments for Ulcerative Colitis: The Personalization Era
New treatments for ulcerative colitis are also ushering in a more personalized era of gastroenterology. Clinicians are increasingly tailoring therapy based on disease severity, genetic biomarkers, and prior treatment response — allowing them to match the right drug to the right patient. For patients who have cycled through multiple therapies, the expanding pipeline offers renewed options, including oral small molecules that provide the convenience of a daily pill rather than infusions or injections.
Looking Ahead
The ulcerative colitis treatment landscape is undergoing its most dynamic transformation in decades. With over a dozen drugs in late-stage clinical trials and several NDA submissions anticipated in the next two years, patients and physicians alike have genuine reasons for optimism. What was once a disease defined by limited options and frequent flare-ups is becoming increasingly manageable — and for many, a condition that can be brought into sustained remission.
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact us
Kanishk
